Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Timber Pharmaceuticals, Inc.BPMX · Entity 110330 | Pres and CEO | June 12, 2019 | June 14, 2019 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | March 09, 2023 | March 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Timber Pharmaceuticals, Inc.
Report date June 12, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2029-06-12 | Direct | 360,000 |
Reported balance
After 2019-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-12 · Grant · Acquired 360,000 · Balance 360,000 F1: This option vests and becomes exercisable ratably over 36 months |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable ratably over 36 months
ZEVRA THERAPEUTICS, INC.
Report date March 09, 2023 · Filed March 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,835 |
Reported balance
After 2023-03-09 transaction · row 1
1 source rowRow 1 · 2023-03-09 · Purchase · Acquired 5,000 · Balance 10,835 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CATALYST PHARMACEUTICALS, INC.
Report date July 15, 2026 · Filed July 17, 2026
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Disposition to issuer · Disposed 383,314 · Balance 0 F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2026-12-02 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 33,500 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-12-30 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2028-12-28 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $18.59 · Expires 2029-12-27 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 29,524 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.12 · Expires 2031-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 23,248 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $22.77 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-15 · Disposition to issuer · Disposed 18,115 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-12-08 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-15 · Disposition to issuer · Disposed 1,414 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-07-15 · Disposition to issuer · Disposed 1,894 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-07-15 · Disposition to issuer · Disposed 5,468 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F5: Each Option was fully vested.
F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2017 Filed May 24, 2017 23:52 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-17-010023 · rdgdoc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-22 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 23, 2017. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 20:13 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,000 | $4.20 | $4,199.90 |
DisclosureSEC source: 0001437749-17-005006 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:12 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001161697-17-000022 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 30,000 shares Expires 2024-01-03 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:12 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001161697-17-000022 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 30,000 shares Expires 2024-01-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.